Acquisition Opportunity ABD was acquired by CVS Health in 2018, indicating a pathway to align products and services with CVS’s expansive pharmacy and specialty care ecosystem, potentially enabling cross-sell of patient support platforms, adherence programs, and care coordination services.

National Reach ABD provides intensive case management regionally and nationally for chronic conditions, suggesting a scalable service model that can be leveraged to pitch integrated care programs, remote patient management platforms, and telehealth-enabled solutions to large, multi-site health systems or payers.

Specialty Focus As a specialty pharmacy serving hepatitis C, HIV, rheumatoid arthritis, and other complex diseases, ABD represents an opportunity to offer specialized medication management tools, adherence monitoring, and outcomes analytics tailored for high-cost, high-need patient populations.

Education and Residency ABD’s collaborations, including a specialty pharmacist residency with UNE, highlight a commitment to clinical expertise; this can translate into partnerships for training programs, clinical decision support integrations, and continuing education content partnerships.

Growth and Financing With reported revenue in the 25 to 50 million range and a history of acquisitions and growth through BelHealth, there is potential to approach ABD for enterprise software, analytics, or marketplace partnerships that support scaling operations, compliance, and performance metrics.